Ellen Moquete

TL;DR: The ARUBA trial showed that medical management alone is superior to medical management with interventional therapy for the prevention of death or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months.

TL;DR: Mitral-valve repair provided a more durable correction of mitral regurgitation but did not significantly improve survival or reduce overall adverse events or readmissions and was associated with an early hazard of increased neurologic events and supraventricular arrhythmias.

TL;DR: Replacement provided a more durable correction of mitral regurgitation, but there was no significant between-group difference in clinical outcomes.

TL;DR: The addition of atrial fibrillation ablation to mitral-valve surgery significantly increased the rate of freedom from atrialfibrillation at 1 year among patients with persistent or long-standing persistent atrial Fibrillation, but the risk of implantation of a permanent pacemaker was also increased.

TL;DR: In patients with moderate ischemic mitral regurgitation, the addition of mitral-valve repair to CABG did not result in a higher degree of left ventricular reverse remodeling, and at 1 year this trial did not show a clinically meaningful advantage.